OBJECTIVE: Evidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries. METHODS: Information on age, SLE duration, cancer date, and histology was available. We analyzed information on histological type and performed multivariate logistic regression analyses of histological types according to age, SLE duration, and calendar year. RESULTS: We studied 180 breast cancers in the SLE cohort. Of the 155 cases with histology information, 11 were referred to simply as 'carcinoma not otherwise specified'. In the remaining 144 breast cancers, the most common histological type was ductal carcinoma (n = 95; 66%) followed by lobular adenocarcinoma (n = 11; 8%), 15 cancers were of mixed histology, and the remaining ones were special types. In our regression analyses, the independent risk factors for lobular versus ductal carcinoma was age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.01-1.14] and for the 'special' subtypes it was age (OR 1.06, 95% CI 1.01-1.10) and SLE duration (OR 1.05, 95% CI 1.00-1.11). CONCLUSIONS: Generally, up to 80% of breast cancers are ductal carcinomas. Though our results are not definitive, in the breast cancers that occur in SLE, there may be a slight decrease in the ductal histological type. In our analyses, age and SLE duration were independent predictors of histological status.
OBJECTIVE: Evidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries. METHODS: Information on age, SLE duration, cancer date, and histology was available. We analyzed information on histological type and performed multivariate logistic regression analyses of histological types according to age, SLE duration, and calendar year. RESULTS: We studied 180 breast cancers in the SLE cohort. Of the 155 cases with histology information, 11 were referred to simply as 'carcinoma not otherwise specified'. In the remaining 144 breast cancers, the most common histological type was ductal carcinoma (n = 95; 66%) followed by lobular adenocarcinoma (n = 11; 8%), 15 cancers were of mixed histology, and the remaining ones were special types. In our regression analyses, the independent risk factors for lobular versus ductal carcinoma was age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.01-1.14] and for the 'special' subtypes it was age (OR 1.06, 95% CI 1.01-1.10) and SLE duration (OR 1.05, 95% CI 1.00-1.11). CONCLUSIONS: Generally, up to 80% of breast cancers are ductal carcinomas. Though our results are not definitive, in the breast cancers that occur in SLE, there may be a slight decrease in the ductal histological type. In our analyses, age and SLE duration were independent predictors of histological status.
Authors: S Bernatsky; J F Boivin; L Joseph; S Manzi; E Ginzler; M Urowitz; D Gladman; P Fortin; C Gordon; S Barr; S Edworthy; S C Bae; M Petri; J Sibley; D Isenberg; A Rahman; K Steinsson; C Aranow; M A Dooley; G S Alarcon; J Hanly; G Sturfelt; O Nived; J Pope; S Ensworth; R Rajan; H El-Gabalawy; T McCarthy; Y St Pierre; A Clarke; R Ramsey-Goldman Journal: Arthritis Rheum Date: 2005-10-15
Authors: Sasha Bernatsky; Rosalind Ramsey-Goldman; Jeremy Labrecque; Lawrence Joseph; Jean-Francois Boivin; Michelle Petri; Asad Zoma; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Steven Edworthy; Soren Jacobsen; Caroline Gordon; Mary Anne Dooley; Christine A Peschken; John G Hanly; Graciela S Alarcón; Ola Nived; Guillermo Ruiz-Irastorza; David Isenberg; Anisur Rahman; Torsten Witte; Cynthia Aranow; Diane L Kamen; Kristjan Steinsson; Anca Askanase; Susan Barr; Lindsey A Criswell; Gunnar Sturfelt; Neha M Patel; Jean-Luc Senécal; Michel Zummer; Janet E Pope; Stephanie Ensworth; Hani El-Gabalawy; Timothy McCarthy; Lene Dreyer; John Sibley; Yvan St Pierre; Ann E Clarke Journal: J Autoimmun Date: 2013-02-12 Impact factor: 7.094
Authors: Marieke W J Louwman; Martine Vriezen; Mike W P M van Beek; M Cathelijne B J E Tutein Nolthenius-Puylaert; Maurice J C van der Sangen; Rudi M Roumen; Lambertus A L M Kiemeney; Jan Willem W Coebergh Journal: Int J Cancer Date: 2007-07-01 Impact factor: 7.396
Authors: S Bernatsky; L Joseph; J-F Boivin; C Gordon; M Urowitz; D Gladman; P R Fortin; E Ginzler; S-C Bae; S Barr; S Edworthy; D Isenberg; A Rahman; M Petri; G S Alarcón; C Aranow; M-A Dooley; R Rajan; J-L Sénécal; M Zummer; S Manzi; R Ramsey-Goldman; A E Clarke Journal: Ann Rheum Dis Date: 2007-06-01 Impact factor: 19.103
Authors: Gaynor J Bates; Stephen B Fox; Cheng Han; Russell D Leek; José F Garcia; Adrian L Harris; Alison H Banham Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544
Authors: S M Gadalla; S Amr; P Langenberg; M Baumgarten; W F Davidson; C Schairer; E A Engels; R M Pfeiffer; J J Goedert Journal: Br J Cancer Date: 2009-02-03 Impact factor: 7.640
Authors: May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke Journal: Best Pract Res Clin Rheumatol Date: 2017-11-10 Impact factor: 4.098
Authors: S Bernatsky; R Ramsey-Goldman; M Petri; M B Urowitz; D D Gladman; P R Fortin; E Ginzler; J Romero-Diaz; C Peschken; S Jacobsen; J G Hanly; C Gordon; O Nived; E H Yelin; D Isenberg; A Rahman; S-C Bae; L Joseph; T Witte; G Ruiz-Irastorza; C Aranow; D Kamen; G Sturfeldt; W D Foulkes; J E Hansen; Y St Pierre; P Chrétien Raymer; B Tessier-Cloutier; A E Clarke Journal: Lupus Date: 2016-09-30 Impact factor: 2.911
Authors: Philip W Noble; Sasha Bernatsky; Ann E Clarke; David A Isenberg; Rosalind Ramsey-Goldman; James E Hansen Journal: Nat Rev Rheumatol Date: 2016-03-24 Impact factor: 20.543
Authors: Waseem Khaliq; Rehan Qayyum; Jeffrey Clough; Dhananjay Vaidya; Antonio C Wolff; Diane M Becker Journal: Breast Cancer Res Treat Date: 2015-05-10 Impact factor: 4.872